Back to Awarded Treatment Trials


Awarded Trial: BPN-2

Grant ID

BPN-2

Illness

Bipolar Disorder

Primary Drug/Intervention

Ethyl Eicosapentanoic Acid

Primary Dosage

6 grams/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Keck

Sample Size

121

Duration of Study Period for Each Subject

4 weeks

Outcome Measurements

Inventory of Depressive Symptoms, CGI-BP

Results

Fifty nine subjects with bipolar depression and 62 subjects with rapid cycling bipolar disorder were randomized to receive 6 grams per day of ethyl-eicosapentanoic acid (EPA) or placebo adjunctive to mood stabilizers for 4 months. There was no significant difference betwen EPA or placebo for rating of depression (Inventory of Depressive Symptoms) or rapid cycling (CGI-BP).

Publication

Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, Altshuler LL, Kupka R, Nolen WA, Leverich GS, Denicoff KD, Grunze H, Duan N, Post RM. Double-Blind, Randomized, Placebo-Controlled Trials of Ethyl-Eicosapentanoate in the Treatment of Bipolar Depression and Rapid Cycling Bipolar Disorder. Biol Psychiatry. 2006 Nov 1;60(9):1020-2.

Link

http://www.ncbi.nlm.nih.gov/pubmed/16814257

PI Name

Paul Keck

Degree

MD

Center

N/A

Institution

University of Cincinnati College of Medicine

Address

231 Albert Sabin Way

City or Town

Cincinnati

State or Province

OH

Zip or Postal Code

45267

Country

USA

Email Address

KECKPE@UCMAIL.UC.EDU